Sitagliptin/Metformin Hydrochloride (Zydus Lifesciences)

西格列汀/盐酸二甲双胍 (Zydus Lifesciences)

Report date: 2025/07/18 17:32:49

Base Information

Drug NameSitagliptin/Metformin Hydrochloride (Zydus Lifesciences)
Drug Alias NameSitagliptin and Metformin HCl (Zydus Lifesciences)Metformin/sitagliptin extended release (Zydus Lifesciences)ZITUVIMETZituvimet
ClassificationSmall molecules
Mechanisms of ActionProtein kinase AMP-activated non-catalytic subunit beta 1 activatorsDipeptidyl peptidase IV inhibitors
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1Dipeptidyl peptidase IV
Therapy Area/IndicationsDiabetes Mellitus, Type 2
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/11/03
Country/TerritoryUnited States
CombinationsYes
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesZydus Lifesciences Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZydus Lifesciences Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus, Type 2
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A